Histogen Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2019-12-23: Form 8-K; Period of report 2019-12-18; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2019-11-27: Form 8-K; Period of report 2019-11-27; Description 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; Details 3.01.
- 2019-11-18: Form 8-K; Period of report 2019-11-18; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2019-11-07: Form 8-K; Period of report 2019-11-06; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2019-12-23 | 8-K | 2019-12-18 | 1.01 Entry into a Material Definitive Agreement | 1.01 On December 18, 2019, Conatus Pharmaceuticals Inc. (the “Company”) and Pacific Real Estate Partnership (“Subtenant”) entered into a Sublease Agreement (the “Sublease”), pursuant to which the Company agreed to sublet to Subtenant approximately 13,225 rentable square feet of office space (the “Premises”), which the Company currently leases, at 16745 West Bernardo Drive, San Diego, CA 92127. | f8k_122319.htm |
| 2019-11-27 | 8-K | 2019-11-27 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On November 27, 2019, Conatus Pharmaceuticals Inc. (the “Company”) received approval from the Nasdaq Stock Market LLC (“Nasdaq”) to transfer the listing of the Company’s common stock from the Nasdaq Global Market to the Nasdaq Capital Market (the “Approval”). | d838166d8k.htm |
| 2019-11-18 | 8-K | 2019-11-18 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Effective as of November 18, 2019, upon the recommendation of the nominating and corporate governance committee, and pursuant to the bylaws of Conatus Pharmaceuticals Inc. (the “Company”), the Board of Directors (the “Board”) of the Company appointed Kathleen D. Scott to the Board. | f8k_111819.htm |
| 2019-11-07 | 8-K | 2019-11-06 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On November 6, 2019, Michelle L. Vandertie, the Vice President of Finance and Principal Accounting Officer of Conatus Pharmaceuticals Inc. (the “Company”), notified the Company of her decision to resign, effective as of November 30, 2019. | d799401d8k.htm |
| 2019-11-05 | 8-K | 2019-11-05 | 2.02 Results of Operations and Financial Condition | 2.02 On November 5, 2019, Conatus Pharmaceuticals Inc. issued a press release announcing its financial results for the quarter and nine months ended September 30, 2019. | f8k_110519.htm |
| 2019-10-04 | 8-K | 2019-09-30 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. 1.02 On September 30, 2019, Conatus Pharmaceuticals Inc. (“Conatus”) and Novartis Pharma AG (“Novartis”) entered into an amendment (the “Amendment”) to the Option, Collaboration and License Agreement, dated December 19, 2016 (the “Collaboration Agreement”), pursuant to which Conatus and Novartis mutually agreed to terminate the Collaboration Agreement, effective September 30, 2019. | d800416d8k.htm |
| 2019-09-24 | 8-K | 2019-09-20 | 2.05 Costs Associated with Exit or Disposal Activities; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 2.05 On September 20, 2019, Conatus Pharmaceuticals Inc. (the “Company”) commenced a restructuring plan that includes reducing staff by approximately 40% in order to extend the Company’s resources. 5.02 In addition, as part of the restructuring described above, on September 20, 2019, David T. Hagerty, M.D. announced his intention to resign as Executive Vice President, Clinical Development of the Company. | d798689d8k.htm |
| 2019-08-06 | 8-K | 2019-08-06 | 2.02 Results of Operations and Financial Condition | 2.02 On August 6, 2019, Conatus Pharmaceuticals Inc. issued a press release announcing its financial results for the quarter and six months ended June 30, 2019. | f8k_080619.htm |
| 2019-08-01 | 8-K | 2019-07-31 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On August 1, 2019, Conatus Pharmaceuticals Inc. (“Conatus”) agreed to allow seven of its current employees, including Steven J. Mento, Ph.D., Keith W. Marshall, Ph.D., Alfred P. Spada, Ph.D. and Michelle Vandertie, to exchange all or a portion of their existing options to purchase shares of Conatus common stock granted under the Conatus Pharmaceuticals Inc. 2013 Incentive Award Plan (the “Equity Plan”) or granted as an employment inducement award pursuant to NASDAQ Listing Rule 5635(c)(4) for a lesser number of new restricted stock units, as described below, provided that options were not eligible for exchange if the grant of the new restricted stock units would have resulted in a violation of the annual award limits under the Equity Plan. | d748546d8k.htm |
| 2019-07-01 | 8-K | 2019-06-27 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 Conatus Pharmaceuticals Inc. (the “Company”) held its annual meeting of stockholders on June 27, 2019. | f8k_070119.htm |
| 2019-06-24 | 8-K | 2019-06-24 | 2.05 Costs Associated with Exit or Disposal Activities; 8.01 Other Events | 2.05 On June 24, 2019, Conatus Pharmaceuticals Inc. (the “Company”) commenced a restructuring plan that includes reducing staff by approximately 40% and suspending development of its inflammasome disease candidate, CTS-2090, in order to extend the Company’s resources. 8.01 On June 24, 2019, the Company announced that top-line results from the Company’s ENCORE-LF clinical trial of emricasan did not meet its primary endpoint and the Company is discontinuing further treatment of patients enrolled in the ENCORE-LF clinical trial. | f8k_062419.htm |
| 2019-05-31 | 8-K | 2019-05-29 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On May 29, 2019, Conatus Pharmaceuticals Inc. (the “Company”) received a letter from the Nasdaq staff indicating that, for the last thirty consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Global Market under Nasdaq Listing Rule 5450(a)(1). | f8k_053119.htm |
| 2019-05-15 | 8-K | 2019-05-15 | 7.01 Regulation FD Disclosure | 7.01 Executive management of Conatus Pharmaceuticals Inc. will be presenting an updated inflammasome program presentation at various upcoming meetings on or after May 15, 2019. | d742061d8k.htm |
| 2019-05-02 | 8-K | 2019-05-02 | 2.02 Results of Operations and Financial Condition | 2.02 On May 2, 2019, Conatus Pharmaceuticals Inc. issued a press release announcing its financial results for the quarter ended March 31, 2019. | f8k_050219.htm |
| 2019-04-02 | 8-K | 2019-04-02 | 7.01 Regulation FD Disclosure | 7.01 Executive management of Conatus Pharmaceuticals Inc. will be presenting an updated corporate presentation at various upcoming meetings with securities analysts, investors and others beginning on April 8, 2019. | f8k_040219.htm |
| 2019-03-21 | 8-K | 2019-03-21 | 8.01 Other Events | 8.01 On March 21, 2019, Conatus Pharmaceuticals Inc. (the “Company”) announced top-line results from the Company’s Phase 2b ENCORE-NF clinical trial of emricasan, the Company’s first-in-class, orally active pan-caspase inhibitor, in patients with biopsy-confirmed nonalcoholic steatohepatitis (“NASH”) and liver fibrosis. | f8k_032119.htm |
| 2019-03-08 | 8-K | 2019-03-08 | 2.02 Results of Operations and Financial Condition | 2.02 On March 8, 2019, Conatus Pharmaceuticals Inc. issued a press release announcing its financial results for the quarter and full year ended December 31, 2018. | f8k_030819.htm |